BlockchAIn Digital Infrastructure (AIB) : 5-month performance

BlockchAIn Digital Infrastructure became a publicly traded company on the NYSE American under the ticker AIB on March 16, 2026, following a business combination rather than a traditional initial public offering (IPO). 

Listing Date: March 16, 2026

Previous Name: BlockchAIn Digital Infrastructure, Inc.

Name Change: Switched to AIB Data Centers Inc. in June 2026.

Exchange / Ticker: NYSE American: AIB

Transaction Type: Business combination (succeeding Signing Day Sports, Inc.)

Strategic Focus: Transitioning operations from Bitcoin mining to high-performance computing (HPC) and artificial intelligence (AI) data center hosting.

Website https://www.aib.us/

Business Strategy

Power-First Model: Focuses on securing utility capacity and energy services agreements before starting development.
Asset Conversion: Converts powered land and legacy crypto-mining infrastructure into high-density, AI-ready data center capacity.
Operations: Provides modular electrical and facility hosting systems while tenants supply their own hardware and GPUs. 

Signing Day Sports went public on November 14, 2023, raising $6 million by offering 1.2 million shares at $5.00 per share on the NYSE American under the ticker symbol SGN. The student-athlete recruiting platform later combined with BlockchAIn Digital Infrastructure in March 2026

IPO and Post-IPO Timeline

Initial Filing: First submitted paperwork to the SEC in 2023 with multiple downsized terms before finalizing.
Offering Details: Offered 1.2 million shares at $5.00 to raise $6 million with Boustead Securities as the sole bookrunner.
Subsequent Capital & Merger: Executed additional public offerings (such as a $5.6 million offering in early 2026) and subsequently moved forward with a business combination with BlockchAIn Digital Infrastructure approved in March 2026

==StableCoinX (USDE) : 2-month performance,

StablecoinX Inc., a stablecoin infrastructure company, focuses on the Ethena digital dollar ecosystem. It offers infrastructure services, stablecoin middleware software, and stablecoin distribution services. The company is based in Frisco, Texas.

Sector: Financial Services

Industry: Capital Markets

https://stablecoinx.com

StablecoinX completed its public market debut on June 26, 2026, via a business combination with the special purpose acquisition company (SPAC) TLGY Acquisition Corp. Its Class A common stock trades on Nasdaq under the ticker symbol USDE. 

Public Listing Details

Transaction Date: June 26, 2026 (following the closure of the merger with TLGY Acquisition Corp. on June 25, 2026).
Exchange / Ticker: Nasdaq Capital Market under USDE (Class A shares) and USDEW (warrants).
Core Focus: Functioning as a public stablecoin infrastructure firm and treasury vehicle centered around the Ethena Labs ecosystem, holding a multi-year treasury strategy in ENA governance tokens.
Leadership: Led by CEO Edward Chen

Apnimed (APMD) began trading on the Nasdaq on Fri 31 Jul 26

Sector: Pharmaceutical industry
Employees 65

Founded by Lawrence G. Miller, Barry Wohl and Luigi Taranto Montemurro in 2017 

Headquartered in Cambridge, MA
Website apnimed.com
Apnimed opened at $22 after pricing IPO at $16/share 

 

• Apnimed (APMD) is off to a successful public-market debut, with its upsized 12.0 mln share IPO pricing at $16 -- the top of its $14--$16 range -- before opening at $22 for a 38% gain, signaling strong investor demand for the late-stage sleep-medicine developer.
• The biopharmaceutical company is developing oral therapies for sleep-related breathing disorders, led by Oxnimbi, also known as AD109, a once-nightly combination drug designed to improve upper-airway muscle activity and prevent airway collapse in patients with obstructive sleep apnea.
• APMD's primary end market is the large OSA population, where current treatment is dominated by devices such as CPAP, giving a convenient oral therapy the potential to expand diagnosis, treatment adoption, and patient compliance if approved.
• The company submitted an NDA for Oxnimbi in April 2026 following positive Phase 3 trials, and the FDA accepted the application for review in July, making regulatory approval and commercialization the central near-term catalysts for the story.
• For the three months ended March 31, 2026, APMD reported $84.8 mln of related-party revenue, up sharply from $3.1 mln a year earlier, while income from operations swung to $68.0 mln from a $27.1 mln loss.
• That financial improvement should be viewed cautiously, however, because the revenue was tied primarily to licensing, know-how, and research-service arrangements with its SASS joint venture rather than recurring commercial product sales, meaning the IPO's longer-term success will ultimately depend on Oxnimbi's approval, launch execution, reimbursement, and physician and patient adoption.